Compare IDEXX Laboratories, Inc. (IDXX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Annaly Capital Management, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Annaly Capital Management, Inc. trades at $22.79 (market cap $16.63B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.7× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NLY | |
|---|---|---|
Market Cap | $44.48B | $16.63B |
Sector | Health | Financials |
52-Week High | $766.68 | $24.40 |
52-Week Low | $520.87 | $19.96 |
Enterprise Value | $45.38B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
NLY trades at $22.73, down 1.22% today, with a bullish technical signal and strong earnings beat history. The stock shows a low P/E of 7.42 and a 13% dividend yield, supported by recent analyst upgrades. Revenue grew to $2.24B in 2025, with net income margin at 91.17%, though cash flow from operations declined to $693M. The consensus price target is $24.80, implying 9% upside.
Outlook remains positive given earnings momentum and high yield, but risks include interest rate sensitivity and elevated debt-to-asset ratio of 23.55. Institutional sentiment is bullish with 57% buy ratings, though macroeconomic shifts could pressure mortgage REIT performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
